|
| Code | Diagnosis | Comment | Score |
| anonymous | Low grade lymphoma infiltrate | CD3, L26, MPO immunostains | 70 |
| anonymous | lymphoma | perform immunostaining of hematolymphoid marker such as LCA,L26,CD3,etc to assess diagnosis. | 50 |
| anonymous | Lymphoma | perform hematolymphoid marker immunostaining of LCA, L26,CD3 etc...to assess diagnosis. | 50 |
| anonymous | Haematolymphoid malignancy, 100% | Favour medium sized lymphoma Immunostaining with CD3, CD20, MPO, Tdt Immunostain for MNF116 to rule out carcinoma. | 100 |
| anonymous | Hematolymphoid malignancy (with "blastoid" appearance) | Immunohistochemical studies to demonstrate lineage of the tumor cells e.g. blastoid mantle cell lymphoma, blastic plasmacytoid lymphoma, granulocytic sarcoma. Panel may include CD3, CD20, bcl-1, Myeloperoxidase, CD56, etc. | 100 |
| anonymous | HEMATOLYMPHOID MALIGNANCY. Favor small cell lymphoma eg. maltoma. Other ddx: mantle cell lymphoma, B-CLL. | Other ddx, granulocytic sarcoma, T-cell lymphoma including gamma delta type. Remote ddx: invasive lobular carcinoma. Do B and T markers, CD5/10/23, myeloperoxidase, CK. Also to exclude primary elsewhere. | 100 |
| anonymous | Myeloid sarcoma (granulocytic sarcoma) (100%) | nil | 100 |
| anonymous | Breast - hematolymphoid neoplasm, favor granulocytic sarcom 100% | Special stain chloroacetate esterase for supporting diagnosis. Also to correlate with blood and marrow findings. | 100 |
| anonymous | Malignant infiltrate 100% | Differential diagnosis includes invasive lobular carcinoma and malignant lymphoma. Immunostains for cytokeratin and LCA are useful to differentiate the two. The resection margin is involved. | 50 |
| anonymous | Malignant tumour. DDx are haematolymphoid malignancy and lobular carcinoma | Immunohistochemical stains to differentiate the type of malignancy | 50 |
| anonymous | Involved by Chronic lymphocytic leukemia / Small lymphocytic lymphoma. | nil | 30 |
| anonymous | HAEMATOLYMPHOID NEOPLASM, favour medium sized lymphoma. Differential diagnosis includes myeloid sarcoma and low grade B cell lymphoma. | nil | 100 |
| anonymous | Hematolymphoid malignancy (100%) | nil | 30 |
| anonymous | Favor Haematolymphoid malignancy (including granulocytic/myeloid sarcoma) over small cell invasive lobular carcinoma 100% | In real life, one will always perform immunohistochemical study, starting with epithelial (cytokeratin) and lymphoid (LCA, CD3, CD20) markers, followed by E-cad and p120-catenin if cytokeratin positive and possible MPO (for positive diagnosis of granulocytic/myeloid sarcoma). | 100 |
| anonymous | hematolymphoid malignancy, favor granulocytic sarcoma (100%) | Perform immunostaining to confirm the diagnosis and to rule out lymphoma and carcinoma: MPO, Tdt, CD3, CD20, cytokeratin | 100 |
| anonymous | Breast: atypical lymphoid infiltration favors malignant lymphoma of small lymphoid cells, including small lymphocytic lymphoma (positive for CD23 and CD5), mantle cell lymphoma ( positive for cyclin D1), extranodal marginal cell lymphoma (negative for CD5, CD23, cyclin D1) and leukemic infiltration should also be ruled out (positive MPO) by performing relevant immunohistochemical stains. (100% probability) | nil | 100 |
| anonymous | Lymphoid lesion. ? maltoma | nil | 30 |
| anonymous | Malignant lymphoid infiltrate, consistent with low-grade lymphoma (90%) Invasive lobular carcinoma (10%) | Confirm by performing CD3, CD20, MNF116 and E-Cadherin immunostains | 50 |
| anonymous | Granulocytic sarcoma (70%), lymphoblastic lymphoma (30%) | Do immunohistochemistry myeloperoxidase to confirm granulocytic sarcoma; and TdT to confirm lymphoblastic lymphoma | 100 |